Skip to Content
Translational Research Program (TRP)
Last Updated: 09/22/16

Cervical SPOREs

Cervical cancer development is driven by the transforming abilities of the human papillomavirus (HPV). Although the incidence of cervical cancer is fairly low in the United States due to the advent of the “pap” smear test (12,990 new cases and 4,120 deaths are projected in 2016), it is a major health threat in the Third World and developing countries, with an overall worldwide incidence of over 500,000 cases in 2012. The Johns Hopkins University Cervical SPORE was first funded in 2013, and its major activities are focused on the development of the next generation of preventive and therapeutic vaccines for cervical cancer and its precursor lesions.

Johns Hopkins University

T.C. Wu, MD, PhD [Click Here]
Departments of Pathology, Oncology,
Obstetrics and Gynecology and
Molecular Microbiology and Immunology
Johns Hopkins University
School of Medicine
Department of Pathology
1550 Orleans Street, CRB II Room 309
Baltimore, MD 21231
Tel: (410) 614-3899
Fax: (443) 287-4295

For more information on this specific SPORE’s institution, please visit: